MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Condition:   Follicular Lymphoma and Marginal Zone Lymphoma Intervention:   Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection, lenalinomide Sponsor:   Beijing Mabworks Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials